Purchase this article with an account.
K. Warren, S. M. Hariprasad, D. Callanan, S. Gainey; Treatment of Acute and Chronic Cystoid Macular Edema With Nepafenac 0.1% (NevanacTM). Invest. Ophthalmol. Vis. Sci. 2007;48(13):5465.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report on the efficacy of nepafenac 0.1% in the treatment of acute and chronic cystoid macular edema (CME).
A retrospective case study evaluating retinal thickness and visual outcomes in patients with either acute or chronic CME.
We describe six patients with CME who were treated with the NSAID nepafenac 0.1%: Three patients with acute post-operative CME following cataract surgery and three patients with chronic macular edema secondary to uveitis. In the 3 acute cases, a diagnosis of clinical CME was made by clinical exam and OCT. Treatment with three-times-daily topical nepafenac 0.1% was initiated, with or without concomitant steroids. After 3-4 weeks of treatment, improvements in both retinal thickness (mean decrease of 231.7 µm) and visual acuity (mean improvement of 2.0 lines) were observed in all cases. Three eyes with documented chronic CME that had failed previous steroid therapy with or without concomitant NSAIDs, were started on topical nepafenac 0.1% three times daily with or without concurrent steroid treatment. This group demonstrated similar improvements in retinal thickness (mean decrease of 236.7 µm) and visual acuity (mean improvement of 1.8 lines) similar to those with acute CME.
Treatment with topical nepafenac 0.1% with or without concomitant steroids reduced retinal thickness and improved visual acuity in patients with acute and chronic CME. Nepafanac is a promising drug for the treatment of CME and warrants further investigation of its use in the prevention and treatment of posterior segment inflammation.
This PDF is available to Subscribers Only